Steroidal lactones as inhibitors of 17β-hydroxysteroid dehydrogenase type 5: Chemical synthesis, enzyme inhibitory activity, and assessment of estrogenic and androgenic activities

European Journal of Medicinal Chemistry

Volumn 44, Issue 2, 2009, Pages 632-644

  Bydal, Patrick ^a   Luu The, Van ^a   Labrie, Fernand ^a   Poirier, Donald ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Androgen; Cancer; Enzyme; Hydroxysteroid dehydrogenase; Inhibitor; Lactone; Steroid; Testosterone

Indexed keywords

3 DEOXYESTRADIOL SULFATE; 5',5',13 TRIMETHYL 4',5',6,7,8,9,11,12,13,14,15,16 DODECAHYDROSPIRO(CYCLOPENTA[A]PHENANTHRENE 17,2' PYRAN) 6'(3'H) ONE; ANDROGEN RECEPTOR; ESTRADIOL; ESTROGEN RECEPTOR; GLUCOCORTICOID RECEPTOR; LACTONE DERIVATIVE; PROGESTERONE RECEPTOR; TESTOSTERONE 17BETA DEHYDROGENASE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; ESTROGEN ACTIVITY; HUMAN; HUMAN CELL;

17-HYDROXYSTEROID DEHYDROGENASES; CELL LINE; CELL PROLIFERATION; ENZYME INHIBITORS; HUMANS; LACTONES; MALE; PROSTATIC DISEASES; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; RECEPTORS, GLUCOCORTICOID; RECEPTORS, PROGESTERONE; STEROIDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 60149084693     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2008.03.020     Document Type: Article

References (47)

1. American Cancer Society. Cancer Facts and Figures 2006 (2006), American Cancer Society, Atlanta
2. Huggins C., and Hodges C.V. Cancer Res. 1 (1941) 293-307
3. Gittes R.F. New Engl. J. Med. 24 (1991) 236-245
4. Dufort I., Rheault P., Huang X.F., Soucy P., and Luu-The V. Endocrinology 140 (1999) 568-574
5. Lin H.K., Jez J.M., Schlegel B.P., Peehl D.M., Pachter J.A., and Penning T.M. Mol. Endocrinol. 11 (1997) 1971-1984
6. Penning T.M., Burczynski M.E., Jez J.M., Lin H.K., Ma H., Moore M., Ratnam K., and Palackal N. Mol. Cell. Endocrinol. 171 (2001) 137-149
7. Labrie F. Mol. Cell. Endocrinol. 78 (1991) C113-C118
8. Baulieu E. C. R. Acad. Sci. Paris 251 (1960) 1421-1425
9. Labrie F., Dupont A., Simard J., Luu-The V., and Bélanger A. Eur. Urol. 24 Suppl. 2 (1993) 94-105
10. Labrie F. J. Clin. Endocrinol. Metab. 80 (1995) 1066-1071
11. Labrie F., Bélanger A., Simard J., Luu-The V., and Labrie C. Ann. N.Y. Acad. Sci. 774 (1995) 16-28
12. El-Alfy M., Luu-The V., Huang X.F., Berger L., Labrie F., and Pelletier G. Endocrinology 140 (1999) 1481-1491
13. Laplante Y., and Poirier D. Steroids 73 (2008) 266-271
14. Poirier D. Curr. Med. Chem. 10 (2003) 453-477 (an update of this review was recently accepted in Anti-Cancer Agents in Medicinal Chemistry)
15. F. Labrie, A. Bélanger, S. Gauthier, V. Luu-The, Y. Mérand, D. Poirier, L. Provencher, S.M. Singh, US Patent 6,541,463, 2003.
16. Krazeisen A., Breitling R., Moller G., and Adamski J. Mol. Cell. Endocrinol. 171 (2001) 151-162
17. Brozic P., Golob B., Gomboc N., Lanisnik-Rizner T., and Gobec S. Mol. Cell. Endocrinol. 248 (2006) 233-235
18. Deluca D., Moller G., Rosinus A., Elger W., Hillisch A., and Adamski J. Mol. Cell. Endocrinol. 248 (2006) 218-224
19. Penning T.M., Steckelbroeck S., Bauman D.R., Miller M.W., Jin Y., Peehl D.M., Fung K.M., and Lin H.K. Mol. Cell. Endocrinol. 248 (2006) 182-191
20. Dionne P., Tchédam Ngatcha B., and Poirier D. Steroids 62 (1997) 674-681
21. Tremblay M.R., Boivin R.P., Luu-The V., and Poirier D. J. Enzyme Inhib. Med. Chem. 20 (2005) 153-163
22. Poirier D., Bydal P., Tremblay M.R., Sam K.M., and Luu-The V. Mol. Cell. Endocrinol. 171 (2001) 119-128
23. Bydal P., Auger S., and Poirier D. Steroids 69 (2004) 325-342
24. Luu-The V., Zhang Y., Poirier D., and Labrie F. J. Steroid Biochem. Mol. Biol. 55 (1995) 581-587
25. Lévesque C., Mérand Y., Dufour J.M., Labrie C., and Labrie F. J. Med. Chem. 34 (1991) 1624-1630
26. Poyet P., and Labrie F. Mol. Cell. Endocrinol. 42 (1985) 283-288
27. Raynaud J.P., Ojasoo T., Bouton M.M., and Philibert D. In: Ariens E.J. (Ed). Drug Design vol. 8 (1979), Academic Press, New York 169-214
28. Wakeling A.E. In: Green B., and Leake R.E. (Eds). Steroid Hormones: A Practical Approach (1987), IRL Press, Washington, D.C. 219-236
29. von Angerer E. The Estrogen Receptor as a Target for Rational Drug Design (Molecular Biology Intelligence Unit) (1995), R.G. Landes Company, Austin pp. 19-30
30. Raynaud J.P., and Ojasoo T. In: Harms A.F. (Ed). Innovative Approaches in Drug Research (1986), Elsevier Science Publishers B.V., Amsterdam 47-72
31. Morris J.J., Hughes L.R., Glen A.T., and Taylor P.J. J. Med. Chem. 34 (1991) 447-455
32. Ali H., Rousseau J., and van Lier J.E. J. Steroid Biochem. Mol. Biol. 49 (1994) 15-29
33. Danhaive P.A., and Rousseau G.G. J. Steroid Biochem. 24 (1986) 481-487
34. Teutsch G., Ojasoo T., and Raynaud J.P. J. Steroid Biochem. 31 (1988) 549-565
35. Luo S., Martel C., Sourla A., Gauthier S., Mérand Y., Bélanger A., Labrie C., and Labrie F. Int. J. Cancer 73 (1997) 381-391
36. Luo S., Martel C., Leblanc G., Candas B., Singh S.M., Labrie C., Simard J., Bélanger A., and Labrie F. Endocr. Relat. Cancer 3 (1996) 229-241
37. Asselin J., Melançon R., Moachon G., and Bélanger A. Cancer Res. 40 (1980) 1612-1622
38. Moeller G., and Adamski J. Mol. Cell. Endocrinol. 248 (2006) 47-55
39. Lukacik P., Kavanagh K.L., and Oppermann U. Mol. Cell. Endocrinol. 248 (2006) 61-71
40. Luu-The V. J. Steroid Biochem. Mol. Biol. 76 (2001) 143-151
41. Pelletier G., Luu-The V., Li S., and Labrie F. Cell Tissue Res. 320 (2005) 393-398
42. Qiu W., Zhou M., Mazumdar M., Azzi A., Ghanmi D., Luu-The V., Labrie F., and Lin S.X. J. Biol. Chem. 282 (2007) 8368-8379
43. Sam K.M., Auger S., Luu-The V., and Poirier D. J. Med. Chem. 38 (1995) 4518-4528
44. Tremblay M.R., Lin S.X., and Poirier D. Steroids 66 (2001) 821-831
45. Tchedam-Ngatcha B., Luu-The V., Labrie F., and Poirier D. J. Med. Chem. 48 (2005) 5257-5268
46. Fiszer-Szarfarz B., Skafarz D., and Guevara de Murillo A. Anal. Biochem. 110 (1981) 165-170
47. Simard J., Dauvois S., Haagensen D.E., Lévesque C., Mérand Y., and Labrie F. Endocrinology 126 (1990) 3223-3231